Impact of Age and Symptom Development on SARS-CoV-2 Transmission in Households With Children-Maryland, New York, and Utah, August 2020-October 2021.

COVID-19 SARS-CoV-2 household transmission

Journal

Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 26 05 2022
accepted: 05 08 2022
entrez: 22 8 2022
pubmed: 23 8 2022
medline: 23 8 2022
Statut: epublish

Résumé

Households are common places for spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We investigated factors associated with household transmission and acquisition of SARS-CoV-2. Households with children age <18 years were enrolled into prospective, longitudinal cohorts and followed from August 2020 to August 2021 in Utah, September 2020 to August 2021 in New York City, and November 2020 to October 2021 in Maryland. Participants self-collected nasal swabs weekly and with onset of acute illness. Swabs were tested for SARS-CoV-2 using reverse transcription polymerase chain reaction. We assessed factors associated with SARS-CoV-2 acquisition using a multilevel logistic regression adjusted for household size and clustering and SARS-CoV-2 transmission using a logistic regression adjusted for household size. Among 2053 people (513 households) enrolled, 180 people (8.8%; in 76 households) tested positive for SARS-CoV-2. Compared with children age <12 years, the odds of acquiring infection were lower for adults age ≥18 years (adjusted odds ratio [aOR], 0.34; 95% CI, 0.14-0.87); however, this may reflect vaccination status, which protected against SARS-CoV-2 acquisition (aOR, 0.17; 95% CI, 0.03-0.91). The odds of onward transmission were similar between symptomatic and asymptomatic primary cases (aOR, 1.00; 95% CI, 0.35-2.93) and did not differ by age (12-17 years vs <12 years: aOR, 1.08; 95% CI, 0.20-5.62; ≥18 years vs <12 years: aOR, 1.70; 95% CI, 0.52-5.83). Adults had lower odds of acquiring SARS-CoV-2 compared with children, but this association might be influenced by coronavirus disease 2019 (COVID-19) vaccination, which was primarily available for adults and protective against infection. In contrast, all ages, regardless of symptoms and COVID-19 vaccination, had similar odds of transmitting SARS-CoV-2. Our findings underscore the importance of SARS-CoV-2 mitigation measures for persons of all ages.

Sections du résumé

Background UNASSIGNED
Households are common places for spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We investigated factors associated with household transmission and acquisition of SARS-CoV-2.
Methods UNASSIGNED
Households with children age <18 years were enrolled into prospective, longitudinal cohorts and followed from August 2020 to August 2021 in Utah, September 2020 to August 2021 in New York City, and November 2020 to October 2021 in Maryland. Participants self-collected nasal swabs weekly and with onset of acute illness. Swabs were tested for SARS-CoV-2 using reverse transcription polymerase chain reaction. We assessed factors associated with SARS-CoV-2 acquisition using a multilevel logistic regression adjusted for household size and clustering and SARS-CoV-2 transmission using a logistic regression adjusted for household size.
Results UNASSIGNED
Among 2053 people (513 households) enrolled, 180 people (8.8%; in 76 households) tested positive for SARS-CoV-2. Compared with children age <12 years, the odds of acquiring infection were lower for adults age ≥18 years (adjusted odds ratio [aOR], 0.34; 95% CI, 0.14-0.87); however, this may reflect vaccination status, which protected against SARS-CoV-2 acquisition (aOR, 0.17; 95% CI, 0.03-0.91). The odds of onward transmission were similar between symptomatic and asymptomatic primary cases (aOR, 1.00; 95% CI, 0.35-2.93) and did not differ by age (12-17 years vs <12 years: aOR, 1.08; 95% CI, 0.20-5.62; ≥18 years vs <12 years: aOR, 1.70; 95% CI, 0.52-5.83).
Conclusions UNASSIGNED
Adults had lower odds of acquiring SARS-CoV-2 compared with children, but this association might be influenced by coronavirus disease 2019 (COVID-19) vaccination, which was primarily available for adults and protective against infection. In contrast, all ages, regardless of symptoms and COVID-19 vaccination, had similar odds of transmitting SARS-CoV-2. Our findings underscore the importance of SARS-CoV-2 mitigation measures for persons of all ages.

Identifiants

pubmed: 35991589
doi: 10.1093/ofid/ofac390
pii: ofac390
pmc: PMC9384637
doi:

Types de publication

Journal Article

Langues

eng

Pagination

ofac390

Investigateurs

Meghan L Bentz (ML)
Alex Burgin (A)
Mark Burroughs (M)
Morgan L Davis (ML)
Madden Joseph C (M)
Sarah Nobles (S)
Jasmine Padilla (J)
Mili Sheth (M)
Michael Daugherty (M)
Yan Li (Y)
Anna Kelleher (A)
Ying Tao (Y)
Jing Zhang (J)
Brian Lynch (B)
Adam Retchless (A)
Anna Uehara (A)
Han Jia Ng (HJ)
Christine Council-DiBitetto (C)
Tina Ghasri (T)
Amanda Gormley (A)
Milena Gatto (M)
Maria Jordan (M)
Karen Loehr (K)
Jason Morsell (J)
Jennifer Oliva (J)
Jocelyn San Mateo (JS)
Kristi Herbert (K)
Khadija Smith (K)
Kimberli Wanionek (K)
Cathleen Weadon (C)
Suzanne Woods (S)

Informations de copyright

Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.

Déclaration de conflit d'intérêts

Potential conflicts of interest. Unrelated to this work, Christina A. Porucznik discloses receipt of personal compensation from McKesson Corporation within the past 3 years. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Références

Clin Infect Dis. 2020 Nov 5;71(8):1943-1946
pubmed: 32301964
J Paediatr Child Health. 2022 May;58(5):769-773
pubmed: 34723402
JAMA Pediatr. 2022 Jan 1;176(1):59-67
pubmed: 34623377
Emerg Infect Dis. 2021 Dec;27(12):3009-3019
pubmed: 34695369
N Engl J Med. 2021 Oct 28;385(18):1718-1720
pubmed: 34496200
Lancet Reg Health West Pac. 2021 Dec;17:100299
pubmed: 34746899
Clin Infect Dis. 2020 Nov 19;71(16):2099-2108
pubmed: 32392331
Microorganisms. 2021 Nov 17;9(11):
pubmed: 34835495
Nat Commun. 2021 Dec 13;12(1):7251
pubmed: 34903718
Lancet Infect Dis. 2021 May;21(5):617-628
pubmed: 33476567
BMC Genomics. 2016 Sep 05;17:708
pubmed: 27595578
Lancet Infect Dis. 2022 Feb;22(2):183-195
pubmed: 34756186
JAMA Pediatr. 2021 Nov 1;175(11):1151-1158
pubmed: 34398179
Am J Epidemiol. 2004 Sep 15;160(6):509-16
pubmed: 15353409
Euro Surveill. 2021 Nov;26(44):
pubmed: 34738514
Clin Infect Dis. 2022 May 3;74(9):1675-1677
pubmed: 34463697
Clin Infect Dis. 2021 Oct 5;73(7):1805-1813
pubmed: 33185244
JAMA Netw Open. 2021 Feb 1;4(2):e210304
pubmed: 33635324
Virus Evol. 2021 Jul 30;7(2):veab064
pubmed: 34527285
MMWR Morb Mortal Wkly Rep. 2021 Jan 01;69(5152):1633-1637
pubmed: 33382676
Clin Infect Dis. 2021 Sep 15;73(6):e1261-e1269
pubmed: 33709135
Am J Epidemiol. 2014 Dec 15;180(12):1196-1201
pubmed: 25416593
JAMA Netw Open. 2020 Dec 1;3(12):e2031756
pubmed: 33315116
Emerg Infect Dis. 2020 Oct;26(10):2401-2405
pubmed: 32610037
Lancet Infect Dis. 2020 Oct;20(10):1141-1150
pubmed: 32562601
Int J Infect Dis. 2021 Nov;112:352-361
pubmed: 34600136
PLoS One. 2020 Oct 8;15(10):e0240205
pubmed: 33031427
N Engl J Med. 2021 Sep 2;385(10):954-956
pubmed: 34289272
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
JCI Insight. 2022 Apr 22;7(8):
pubmed: 35316213

Auteurs

Kelsey M Sumner (KM)

Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia, USA.

Ruth A Karron (RA)

Center for Immunization Research, Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.

Melissa S Stockwell (MS)

Division of Child and Adolescent Health, Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York, USA.

Fatimah S Dawood (FS)

Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia, USA.

Joseph B Stanford (JB)

Division of Public Health, Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.

Alexandra Mellis (A)

Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia, USA.

Emily Hacker (E)

Division of Public Health, Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.

Priyam Thind (P)

Division of Child and Adolescent Health, Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York, USA.

Maria Julia E Castro (MJE)

Division of Child and Adolescent Health, Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York, USA.

John Paul Harris (JP)

Division of Child and Adolescent Health, Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York, USA.

Maria Deloria Knoll (M)

International Vaccine Access Center, Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.

Elizabeth Schappell (E)

Center for Immunization Research, Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.

Marissa K Hetrich (MK)

International Vaccine Access Center, Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.

Jazmin Duque (J)

Abt Associates, Cambridge, Massachusetts, USA.

Zuha Jeddy (Z)

Abt Associates, Cambridge, Massachusetts, USA.

Kim Altunkaynak (K)

Abt Associates, Cambridge, Massachusetts, USA.

Brandon Poe (B)

Abt Associates, Cambridge, Massachusetts, USA.

Jennifer Meece (J)

Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.

Elisha Stefanski (E)

Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.

Suxiang Tong (S)

Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia, USA.

Justin S Lee (JS)

Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia, USA.

Ashton Dixon (A)

Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia, USA.

Vic Veguilla (V)

Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia, USA.

Melissa A Rolfes (MA)

Centers for Disease Control and Prevention COVID-19 Response, Atlanta, Georgia, USA.

Christina A Porucznik (CA)

Division of Public Health, Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.

Classifications MeSH